Autopsy report · NCT04060329

Measuring and Improving Coproduction Using coopeRATE

“Reasons associated with COVID-19 pandemic led to cancellation of Phase 2”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 3 months before it stopped.
• 280 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Dartmouth-Hitchcock Medical Center

Sponsor type

University, hospital or other

Conditions

Cystic Fibrosis; Chronic Disease

Interventions

coopeRATE Prompt

Participants

280

Sites

9

Countries

United States

Trials that died the same way

• Evaluation of Skin Cleansers and Skin Protectants in Management of Incontinence-associated Dermatitis
  “Early termination due to COVID-19 pandemic led to inability to reach planned sample size” (65% match in meaning)
• The Norwegian Prednisolone in Early Psychosis Study
  “Stopped because of COVID 19 pandemic” (63% match in meaning)
• A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
  “Phase 2 completed as planned. Due to the evolving landscape of treatments for COVID-19, the placebo-controlled Phase 3 design will not proceed. No patients were actively participating at the time of termination.” (61% match in meaning)
• Three Dimensional Facial Growth Analysis
  “Due to Covid-19 pandemic” (61% match in meaning)
• Yogurt Supplementation to Alter Bone Biomarkers, the Gut Microbiota and Inflammation in Older Adults
  “Due to the onset of the COVID-19 pandemic” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.